Similac

Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt Benckiser Group PLC Following $60 Million Baby Formula Verdict and Subsequent Stock Plummet

Retrieved on: 
Friday, March 15, 2024
Safety, Similac, Reckitt, Extrapyramidal system, Abbott Laboratories, Lysol

​LOS ANGELES, March 15, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTCMKTS: RBGLY) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Reckitt stock. Reckitt investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • ​LOS ANGELES, March 15, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTCMKTS: RBGLY) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Reckitt stock.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • Portnoy Law is initiating an investigation into Reckitt in light of recent events that have led to a significant decline in the company's stock value.
  • This follows an Illinois jury's decision to award $60 million in damages to the plaintiff in a lawsuit involving Reckitt's Enfamil baby formula.

"PREEMIES" DEVASTATED BY COW'S MILK-BASED FORMULA DESERVE JUSTICE

Retrieved on: 
Tuesday, January 24, 2023
Extrapyramidal system, NEC, MDL, Cassidy, Infant, Child, Infection, Formula, Hospital, Surgeon, World Health Organization, Similac, Enfamil, Family, Dairy, Dietary supplement, Tobacco

TORONTO, Jan. 24, 2023 /CNW/ - Families of premature babies fed common infant formula derived from cow's milk deserve justice as they struggle through a life of suffering and financial hardship.

Key Points: 
  • TORONTO, Jan. 24, 2023 /CNW/ - Families of premature babies fed common infant formula derived from cow's milk deserve justice as they struggle through a life of suffering and financial hardship.
  • "Formula milk companies… run advertising that routinely mischaracterizes scientific findings: It's time to stop infant formula marketing practices that endanger children."
  • The lawsuit alleges that cow's milk-based formula manufacturers are liable for misleading and false scientific claims.
  • Yet they have not received proper compensation for the careless use of cow's milk-based formula that was marketed as a super-food.

ABBOTT ALERT: Bragar Eagel & Squire, P.C. is Investigating Abbott Laboratories on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, January 20, 2023
Class Action Lawsuit, Professional Services, Legal, Similac, News, Laboratory, Death, Safety, FDA, NYSE, Bacteria, United, Jeanne Eagels, Telephone, Abbott Laboratories, Complaint, US Foods, Labor Day, Infant, P.C, OSHA, Medical device

Our investigation concerns whether the board of directors of Abbott have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Abbott have breached their fiduciary duties to the company.
  • Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.
  • Prior to February 2022, Abbott had produced 40% of the United States’ infant formula.
  • On February 17, 2022, the US Food and Drug Administration (“FDA”) announced it was investigating four consumer complaints of infant illness related to powdered infant formula produced by Abbott Laboratories in Sturgis.

ABT IMPORTANT DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT

Retrieved on: 
Sunday, October 30, 2022
Titan, Court, Class, I-Space (Chinese company), Advertising, GLOBE, Abbott Laboratories, FDA, Similac, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, NYSE, Infant, Insurance, Tobacco

WHAT TO DO NEXT: To join the Abbott class action, go to https://rosenlegal.com/submit-form/?case_id=8453 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Abbott class action, go to https://rosenlegal.com/submit-form/?case_id=8453 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2022.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ABBOTT LABORATORIES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

Retrieved on: 
Saturday, October 29, 2022
Class Action Lawsuit, Professional Services, Legal, Company, Special warfare combatant-craft crewmen, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, District court, OSHA, Similac, Food, Cronobacter, Abbott Laboratories, Court, News, LLC, FDA, Lists of schools in England, Infant, Laboratory, NYSE, KSF, Firefighter, Insurance, Medical device

This action is pending in the United States District Court for the Northern District of Illinois.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of Illinois.
  • Abbott and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • The case is Pembroke Pines Firefighters & Police Officers Pension Fund v. Abbott Laboratories, No.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Latch, Azure, Abbott, and TuSimple and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, October 27, 2022
Mission statement, Federal Motor Carrier Safety Administration, Company, LTCH, Death, NASDAQ, Safety, OSHA, Labor Day, IPO, Similac, Bacteria, Azure, Defendant, Abbott Laboratories, Journal, Technology, Culture, US Foods, Travel, Compliance, Complaint, News, GLOBE, FDA, Lists of schools in England, Infant, NYSE, Sale, The Wall Street Journal, Accident, United, Public relations, Pharmaceutical industry, Audit, Medical device, P.C, Latch

On this news, Latchs stock fell $0.13, or 12.2%, to close at $0.95 per share on August 26, 2022, on unusually heavy trading volume.

Key Points: 
  • On this news, Latchs stock fell $0.13, or 12.2%, to close at $0.95 per share on August 26, 2022, on unusually heavy trading volume.
  • For more information on the Azure class action go to: https://bespc.com/cases/AZRE
    Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.
  • For more information on the TuSimple class action go to: https://bespc.com/cases/TSP
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Abbott Investors: Please Contact the Portnoy Law Firm to Recover Your Losses; Last Days to Actively Participate in the Case; October 31, 2022

Retrieved on: 
Thursday, October 27, 2022
Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Safety, OSHA, Risk, Similac, Bacteria, Food, Abbott Laboratories, Complaint, News, GLOBE, Review, FDA, Lists of schools in England, Infant, NYSE, Cronobacter sakazakii, United, Life insurance, Risk management, Pharmaceutical industry, Cronobacter

Abbott investors with over $500,000 in losses on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • Abbott investors with over $500,000 in losses on their investment are encouraged to contact Lesley Portnoy, Esq.
  • Please contact attorney Lesley F. Portnoy ,by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • By early 2022, Abbott was responsible for producing 40 percent of the United States infant formula.

ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

Retrieved on: 
Wednesday, October 26, 2022
Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, District court, OSHA, Similac, Food, Abbott, Cronobacter, Abbott Laboratories, Lawyer, News, GLOBE, LLC, FDA, Lists of schools in England, FREE, Infant, Laboratory, NYSE, Firefighter, Medical device

This action is pending in the United States District Court for the Northern District of Illinois.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of Illinois.
  • Abbott investors should visit us at https://claimsfiler.com/cases/nyse-abt-1/ or call toll-free (844) 367-9658.
  • Abbott and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

ABT FINAL DEADLINE MONDAY: GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT

Retrieved on: 
Tuesday, October 25, 2022
Titan, LinkedIn, Advertising, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Class, Facebook, Similac, Food, THE, WHY, Abbott Laboratories, I-Space (Chinese company), Court, GLOBE, TO, Twitter, FDA, Lists of schools in England, Infant, NYSE, Insurance, Tobacco

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.

Key Points: 
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, October 25, 2022
Company, Similac, Labour government, Laboratory, NYSE, Death, District court, GLOBE, NEW, FDA, Infant, Investment, Securities Exchange Act of 1934, Bacteria, Cronobacter sakazakii, News, Food and Drug Administration, United, The Legal 500, Advertising, Court, Safety, Fine chemical, Online gambling, Medical device, Cronobacter, Abbott Laboratories

NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.